MHRA reclassifies Otrivine Extra Dual Relief Nasal Spray Solution
The Medicines and Healthcare products Regulatory Agency has today agreed that Otrivine Extra Dual Relief Nasal Spray Solution will be available through pharmacies without prescription.
Otrivine Extra Dual Relief Nasal Spray contains Ipratropium bromide 0.6mg/ml and xylometazoline hydrochloride 0.5mg/ml.
Following a public consultation, MHRA has agreed to reclassify Otrivine Extra Dual Relief Nasal Spray Solution from a Prescription Only Medicine (POM) to a Pharmacy (P) medicine in the UK for the symptomatic treatment of nasal congestion and rhinorrhoea in connection with common colds.
MHRA is committed to improving access to medicines where it is safe to do so, providing greater choice and better access for the public.